My guess would be sometime in mid to late 2026 if they dont experience any hurdles in trial completion
[DOI] [PMC free article] [PubMed] [Google Scholar] 170.Sacks F.M., Carey V.J., Anderson C.A., Miller E.R., 3rd, Copeland T., Charleston J., Harshfield B.J., Laranjo N., McCarron P., Swain J., et al
Patients should not simply push through severe or persistent symptoms
Inflammatory markers improved
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) not yet licensed by the MHRA or EMA for use in the UK
Impacts included loss of independence (i.e., loss of freedom and/or privacy, inability to leave the pALS or their home), and affected interpersonal relationships, activities, and professional/family life (Figure)